Claims Library Entry
How AI Will Help You Live to 150 (Not Science Fiction)
A special edition of the AI Adopters newsletter exploring how AI is accelerating longevity research, from biological aging clocks to AI-designed drugs and digital twins. The article profiles key players like Insilico Medicine, Deep Longevity, and Human Longevity, Inc., while also examining the biological, ethical, and regulatory challenges ahead. It argues that AI-driven longevity breakthroughs will disrupt insurance, retirement planning, and healthcare delivery for business leaders.
Published March 21, 2025 by Kamil Banc
Lead claim
AI-designed drugs reached human trials in 18 months instead of a decade, accelerating longevity research.
Atomic Claims
What this article supports
Copy individual claims as needed.
Claim 1 · Source summary
AI Aging Clocks
Deep Longevity's AI aging clocks measure biological age using blood markers, DNA methylation, and microbiome data.
Claim 2 · Source summary
AI-Designed Drug Reaches Trials
Insilico Medicine's AI designed Rentosertib, an IPF drug reaching human trials in 18 months.
Claim 3 · Source summary
Insilico's Growing Drug Pipeline
By 2025, Insilico Medicine had over 30 drug candidates with 10 cleared for human trials.
Claim 4 · Source summary
AI Rejuvenates Elderly Mice
GERO.AI achieved systemic rejuvenation in elderly mice using AI-predicted interventions targeting aging.
Claim 5 · Kamil's interpretation
Regulatory Hurdles for Anti-Aging
Aging is not classified as a disease, creating regulatory hurdles for anti-aging treatment approval.
Evidence
Context behind the claims
Quote
"The research community has shifted from treating individual diseases to targeting the root causes of aging itself."
Key statistics
$2.7 billion to $4.1 billion
The longevity market is projected to grow from $2.7 billion in 2023 to $4.1 billion by 2030.
Exceeded $1 billion
Venture funding in longevity research has surpassed $1 billion, with investors including Sam Altman, Jeff Bezos, and Peter Thiel.
18 months
Insilico Medicine's AI identified both the drug target and designed the Rentosertib molecule in 18 months, versus the typical decade-long process.
30+ candidates, 10 in trials
By 2025, Insilico Medicine had accumulated more than 30 AI-designed drug candidates, with 10 cleared for human trials.
Supporting context
The article draws on company announcements, peer-reviewed research, and market analyses to map AI's role in longevity science, citing sources from King's College London, PubMed, GERO.AI, and Deloitte. Practitioners can apply these insights by understanding how biological aging clocks, AI-driven drug discovery pipelines, and digital twin assessments shift healthcare from reactive treatment to prevention. For business leaders, the practical takeaway is anticipating disruption to insurance models, retirement planning, and workforce dynamics as longevity technologies mature. The author balances optimism with caution, flagging biological complexity, data quality, ethics, and regulation as unresolved obstacles before lifespan predictions like 150 years become reality.
How to Cite
Use the claim-level citation when you need a precise statement. Use the article or claims-collection citation when you want the wider argument and source context.
Individual Claim
Best when you need to cite one atomic claim directly inside a memo, deck, research note, or AI output.
"[claim text]" (Banc, Kamil, 2025, https://kbanc.com/claims-library/how-ai-will-help-you-live-to-150-not-science-fiction)Original Article
Use this when you want to cite the full newsletter article at AI Adopters Club rather than the structured claims page.
Banc, Kamil (2025, March 21, 2025). How AI Will Help You Live to 150 (Not Science Fiction). AI Adopters Club. https://aiadopters.club/p/the-longevity-moonshotClaims Collection
Use this when you want to reference the full structured claims collection on this page.
Banc, Kamil (2025). How AI Will Help You Live to 150 (Not Science Fiction) [Structured Claims]. Retrieved from https://kbanc.com/claims-library/how-ai-will-help-you-live-to-150-not-science-fictionAttribution Requirements
- Include the author name: Kamil Banc.
- Include the source: AI Adopters Club or the structured claims page.
- Link to the original article or the claims page you used.
- Indicate any edits or transformations if you changed the wording.
Related Reading
More from the library
Market research isn't hard because data is unavailable—it's hard because people don't know what questions to ask. This article reveals how AI tools like Gemini Deep Research can run the same structured analysis consultants charge $150K for, delivering market entry plans in 20 minutes instead of months.
5 claims
This article discusses how AI can transform customer persona development by focusing on concrete decision criteria instead of superficial demographic details. It outlines a method for using AI to extract meaningful insights about customer needs, pricing strategies, and sales objections.
5 claims
This article explores how AI can help businesses improve their valuation by systematically reducing operational risks and creating more predictable systems. It details five specific AI-powered approaches that can transform a business's attractiveness to potential buyers and increase its market value.
5 claims